T-cell lymphomaDeveloping CAR T-cells for T-lineage malignancies requires minimizing fratricide of engineered T-cells and mitigating the risk of T-cell aplasia, which may be caused by the off-tumor activity of CAR T-cells. We have developed and optimized for clinical evaluation a CAR targeting...
Chen, X. et al. (2023) 'Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.,' Journal of Clinical Oncology, 41(16_su...
部分原因可能与患者选择更合理、更早使用 CAR-Ts 以及更有效的桥接策略有关。2L CAT 的出现使 >2L 适应症大幅减少,与延迟超过2L使用CAR-T相比,2L后使用CAR-T是否真的能带来更好的疗效,还需要进一步的研究来证实。 参考文献: ...
Acute lymphoblastic leukemia (ALL) is a cancer-specific lymphoid cell. Induction and consolidation chemotherapy alone or in combination with different therapeutic approaches remain the main treatment. Although complete or partial remission of the disease can be achieved, the risk of relapse or refractory...
2. Noa G Holtzman, Nirali N Shah.CAR T-cell therapy for indolent lymphoma: a new treatment paradigm?Lancet Oncol . 2021 Dec 8;S1470-2045(21)00648-3
高博医学（血液病）北京研究中心北京高博博仁医院潘静主任聚焦自体 CD7 CAR-T 治疗难治/复发急性T淋巴细胞白血病/淋巴瘤（r/r T-ALL/LBL），在大会发言中分享了题为“Autologous CD7 CAR T-Cell Therapy for Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma”的最新研究成果。此前，潘静主任...
如果您也饱受血液肿瘤或实体瘤困扰，且想寻求CAR-T疗法的帮助，可将治疗经历、近期病理和影像学检查结果、血液检查结果等，提交至医学部，进行初步评估。参考资料 [1]Cwynarski K,et al.TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial[J]. Nature Medicine, 2024: 1-7.https...
CD7靶点CAR-T潜力巨大,或成为多种血液瘤新治疗手段 由于EBV感染,在中国结外NK/T细胞淋巴瘤,鼻型(ENKL)和外周T淋巴瘤,非特指型(PTCL-NOS)是最常见的外周T细胞淋巴瘤(peripheral T-cell lymphoma,PTCL)亚型[3]。PTCL发病率占非霍奇金淋巴瘤的25%~30%[4],一线治疗方案主要为CHOP(环磷酰胺+多柔比星+长春新碱+...
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and available treatments for MCL, this cancer ...
近日，该研究结果以A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma为标题，发表在Nature medicine 杂志上。2019年12月至2021年10月间，共有来自法国23家机构的809位弥散性大B细胞瘤病人注册并预定CAR T疗法 (...